One reason was instrument price. When this became coupled with concerns about long-term viability, it created a downward spiral.
On Tuesday, September 4, 2012 12:42:13 PM UTC-4, John Griessen wrote:
On 09/04/2012 10:34 AM, singlemolecule wrote:--
> commercial uptake has been extremely limited for a variety of reasons
What reasons?
You received this message because you are subscribed to the Google Groups "DIYbio" group.
To post to this group, send email to diybio@googlegroups.com.
To unsubscribe from this group, send email to diybio+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msg/diybio/-/jPhtQsO5mWwJ.
For more options, visit https://groups.google.com/groups/opt_out.
0 comments:
Post a Comment